- Home
- GNLX vs GBLI Comparison
GNLX vs GBLI Comparison
Compare GNLX & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNLX | GBLI |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 395.4M |
| IPO Year | 2022 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GNLX | GBLI |
|---|---|---|
| Price | $2.98 | $26.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 144.8K | 5.1K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $8,000.00 | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ N/A | $89.07 |
| Revenue Growth | N/A | ★ 2.02 |
| 52 Week Low | $2.29 | $25.63 |
| 52 Week High | $8.54 | $34.00 |
Technical Indicators
Market Signals| Indicator | GNLX | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 45.49 |
| Support Level | $2.51 | $25.76 |
| Resistance Level | $3.21 | $28.78 |
| Average True Range (ATR) | 0.15 | 0.51 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 46.84 | 45.73 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.